Vitreoretinal Surgery — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$63,628	11
2022	Research	$60,050	6
2021	Research	$91,642	1
2019	Research	$30,091	1

Breakdown

Who paid Research payments · program years 2019–2023

Novartis Pharmaceuticals Corporation $136,357 3 payments
Genentech, Inc. $95,753 15 payments
Alexion Pharmaceuticals, Inc. $13,300 1 payment

Studies the money was for Research payments · program years 2019–2023

A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $106,266 2 payments
Phase 2 of Ro7171009 in Ga $78,533 12 payments
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $30,091 1 payment
Belvedere $17,220 3 payments
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $13,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.